Possible contributing factors include suboptimal antigen selection, IFN‐γ‐induced PD‐L1 expression during DEX manufacturing, and the need for combination with checkpoint blockade to overcome tumor immunosuppression. This evidence concerns the gene IFNG and neoplasm.